研究業績

MEDICAL RESEARCH

TOP  / 研究業績  / 2021年業績

2021年業績

2021年業績(2021年1月~12月)

 

  1. 著書および論文

①著書

1.寺尾岳, 牧野麻友. 抗不安薬. PocketDrugs2021. 12-13, 医学書院, 東京都. 2021.

2.寺尾岳. 双極性障害の治療. 専門医のための臨床精神神経薬理学テキスト. 289-300, 星和書店,東京. 2021.

②原著

1.Bhagwat N, Barry A, Dickie EW, Brown ST, Devenyi GA, Hatano K, DuPre E, Dagher A, Chakravarty M, Greenwood CMT, Misic B, Kennedy DN, Poline JB. Understanding the impact of preprocessing pipelines on neuroimaging cortical surface analyses. Gigascience. 10:giaa155, 2021.

2.Kawano N, Terao T, Sakai A, Akase M, Hatano K, Shirahama M, Hirakawa H, Kohno K, Ishii N. Maternal overprotection predicts consistent improvement of self-compassion during mindfulness-based intervention and existential approach: a secondary analysis of the EXMIND study. BMC Psychol. 9:20, 2021.

3.Kugimiya T, Ishii N, Kohno K, Kanehisa M, Hatano K, Hirakawa H, Terao T. Lithium in drinking water and suicide prevention: the largest nationwide epidemiological study from Japan. Bipolar Disord. 23:33-40, 2021.

4.Hoaki Y, Terao T. Frequency of participation in a Return-to-Work program predicts successful work restoration but not maintenance. Front Psychiatry. 12:620520, 2021.

5.Hirakawa H, Terao T, Hatano K, Shirahama M, Kugimiya T, Kohno K, Ishii N, Matsuta H, Shimomura T, Fujiki M. Increase in the left hippocampal dentate gyrus head volume after a 4-week bright light exposure in healthy participants: a randomized controlled study. J Psychiatr Res. 145:1-5, 2021.

6.寺尾岳.「別府観光の父」と呼ばれた油屋熊八. 日本病跡学会雑誌. 101:7-19, 2021.

③症例報告

1.Hirakawa H, Terao T, Muronaga M, Ishii N. A case of clozapine-induced creatine kinase elevation after initiation of clozapine with successful continuation. Aust N Z J Psychiatry. 55:633, 2021.

2.Hirakawa H, Terao T, Ishii N, Sakai A, Yamashita H, Kawatani M, Namba S, Goto C. Thought process evolved from rigid to flexible in a patient with bipolar disorder via “Return to Work Program”: a case report. J Nerv Ment Dis. 209:609-611, 2021.

3.Kamei S, Tanaka R, Hirakawa H, Iwao M, Kawanaka R, Tatsuta R, Terao T, Itoh H. A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia. J Pharm Health Care Sci. 7:45, 2021.

④総説

1.Ishii N, Terao T, Hirakawa H. The present state of lithium for the prevention of dementia related to alzheimer’s dementia in clinical and epidemiological studies: a critical review. Int J Environ Res Public Health. 18:7756, 2021.

2.Terao T. Neglected but not negligible aspects of antidepressants and their availability in bipolar depression. Brain Behav. 11:e2308, 2021.

3.寺尾岳. さまざまな対応高齢者の双極性障害. 精神科Resident. 2:38-40, 2021.

4.寺尾岳. Charles Bonnet症候群の幻覚. 脳神経内科. 9:339-344, 2021.

5.寺尾岳. ADHDと双極性障害の併存. 臨床精神医学. 50:345-351, 2021.

6.石井啓義, 平川博文. 10鎮静薬,睡眠薬,抗不安薬使用による認知症. 精神科治療学. 36:228-229, 2021.

7.寺尾岳. 双極性障害. 精神医学. 63:1597-1604, 2021.

⑤その他(レター等)

1.Terao T. Dampening antidepressant effects via 5-HT 1A auto-receptors. Acta Psychiatr Scand. 143:94-95, 2021.

2.Ishii N, Terao T, Hirakawa H. Association between trace levels of lithium in drinking water and COVID-19-associated mortality. Bipolar Disord. 23:100, 2021.

3.Hirakawa H, Ishii N. Did Ian Curtis have bipolar disorder? BipolarDisord. 23:215, 2021.

4.Hirakawa H, Ishii N. Association between mental illness and COVID-19 in South Korea. Lancet Psychiatry. 8:270-271, 2021.

5.Terao T. Antidepressant effects of combined mood stabilizers may account for high placebo response rates. J Clin Psychiatry. 82:21lr13919, 2021.

6.Hirakawa H, Kugimiya T, Ishii N, Terao T. Body mass index, affective temperament and bipolar spectrum disorder. J Affect Disord. 295:3-4, 2021.

7.Terao T. Should medications with little or no efficacy be prescribed when treating bipolar disorder? Bipolar Disord. 23:832-833, 2021.

8.Terao T, Hori H, Buntrock C. Editorial: how to help employees returning to work following depression. Front Psychiatry. 12:714589, 2021.